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annual health care costs (P < 0.01) compared to patients start-
ing other oral antidiabetic agents. CONCLUSIONS: Introduc-
tion of thiazolidinedione therapy in a Medicaid-enrolled type 2
diabetic population was associated with signiﬁcantly greater
treatment persistence and lower healthcare costs in the post-start
year compared to patients starting other oral antidiabetic agents.
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OBJECTIVE: To assess the economic impact of augmentation
therapy [thiazolidinediones (TZDs) or metformin] in type 2 dia-
betes patients who initiated mono-therapy with sulfonylurea.
METHODS: A retrospective cohort design was used to meet the
study objective. Patients newly diagnosed with type 2 diabetes
and initiating therapy with sulfonylurea were identiﬁed during
the four-year period (1998–2001) from a Medicaid claims data-
base. These patients were then followed till they augmented
therapy by adding another oral hypoglycemic agent (TZDs or
metformin) to their regimen. The date of the ﬁrst prescription
for a TZD or metformin was treated as the index date and type
2 diabetes-related costs in the 12-month follow-up period were
assessed. Semi-logarithmic OLS models were used to estimate the
impact of therapy on total diabetes-related costs. Costs were also
examined separately in terms of diabetes-related Emergency
Room (ER)/hospitalization, outpatient and prescription costs
using appropriate two-part models. RESULTS: The ﬁnal cohort
consisted of 298 type 2 diabetes patients who initiated mono-
therapy with sulfonylureas and augmented with either TZDs (n
= 96) or metformin (n = 202). Results of the semi-log OLS model
indicated that patients augmenting sulfonylurea therapy with
metformin incurred 33.27% lower total diabetes-related costs as
compared to those augmenting therapy with TZDs (p < 0.001).
Further breakdown of the costs indicated that there were no sig-
niﬁcant differences in diabetes-related ER/Hospitalization and
outpatient costs between the two groups. However, diabetes-
related prescription costs were 45.47% lower for patients aug-
menting with metformin as compared those augmenting with
TZDs (p < 0.001). CONCLUSION: Patients with type 2 diabetes
initiated on mono-therapy with sulfonylureas and augmenting
with metformin have signiﬁcantly lower type 2 diabetes-related
costs as compared to those augmenting with TZDs, primarily
due to lower prescription costs. The study results can aid in
making important formulary decisions and developing treatment
algorithms for management of type 2 diabetes.
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OBJECTIVES: To determine the cost-effectiveness of adding
angiotensin-converting enzyme inhibitor (ACEI) therapy at
normo-, micro-, and macro-albuminuric stages in Type II dia-
betics. METHODS: We employed a recently published Markov
model depicting nephropathy and cardiovascular disease (CVD)
events among diabetics. Probabilities and costs were from the 
literature. We incorporated a health payer perspective, direct
medical costs with 3% discounting, 1 year cycles, and a 6 year
time horizon. Endpoints were cost/life-year gained (LYG),
cost/death avoided, cost/CVD event averted, cost/patient pre-
vented from dialysis, and cost/composite endpoint (death, CVD
event, dialysis) averted. End-stage renal disease (ESRD) was
excluded from baseline; we assumed these patients would
already be on ACEIs unless contraindicated. We used informa-
tion from the New Mexico Medicaid diabetic population to
ascertain prevalence of each stage of nephropathy and mean age
(68.8 years). The base case included the average cost for ACEIs
at target doses. RESULTS: ACEI treatment is dominant when
initiated in normoalbuminuric patients. Starting ACEI therapy
at microalbuminuria provides incremental cost-effectiveness
ratios (ICERs) of $624.21, $28,000.43, $129.85, and $13.21 per
avoidance of CVD event, dialysis event, death, and LYG, respec-
tively. Waiting until macroalbuminuria causes ACEI therapy to
be dominated for CVD and dialysis events due to lower survival
with the no ACEI alternative. ICERs for death and LYG are
$431.28 and $43.87, respectively. In one-way sensitivity analy-
ses the model was sensitive to ACEI costs and insensitive to dial-
ysis costs. For two-way sensitivity analyses we incorporated
ACEI and dialysis costs and assumed ACEIs further attenuate
the progression from macroalbuminuria to ESRD by 20%.
Across all stages of nephropathy for each cost variation, cost per
additional dialysis event avoided was most impacted in this
analysis. CONCLUSIONS: In most patients, ACEIs should be
initiated upon diagnosis of Type II diabetes to prevent higher
healthcare costs due to more events in the future.
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The increased costs of intensive early management of diabetes
may be offset by a reduction in future complications. As com-
plications of diabetes have been shown to signiﬁcantly contribute
to health care costs, computer simulation models are increasingly
being used to evaluate the likely impact of interventions on the
progression of diabetes as well as the health and economic con-
sequences interventions are likely to accrue over a patient’s life-
time. OBJECTIVES: Stimulate long-term costs and consequences
of an observational 18-month nurse-led multifaceted diabetes
management program aimed at the patient, the health care
providers and the health care system. METHODS: We con-
ducted a cost-effectiveness analysis based on patient-level data
from an observational study involving 404 patients with dia-
betes. Changes in intermediate outcomes (e.g. HbA1c, blood
pressure, cholesterol, and smoking status) at the end of the inter-
vention period were measured and used as risk factors in a Cana-
dian-speciﬁc probabilistic discrete-event model to simulate the
mean difference in cost and expected quality-adjusted life years
(QALYs). Incremental cost-effectiveness ratios were calculated
based on the net cost of health care resources associated with the
program and on effectiveness estimated over a patient’s lifetime.
In the base case, the cost-effectiveness ratio was calculated
assuming the effect of the intervention continued for 1 year using
a discount rate of 3%. RESULTS: The multifaceted diabetes
management program on average reduced HbA1c by 1% (SD
2.3%), systolic blood pressure by 1.4mmHg (SD 21.3), total to
HDL cholesterol ratio by 0.69 (SD 1.30). The incremental cost
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per QALY gained for improved diabetes management for the
program effect lasting for 1 year was $19,573. CONLCUSIONS:
This diabetes management program improved clinical outcomes
for study participants. The results from the cost-effectiveness
analysis reveal that the multifaceted program aimed at increas-
ing the continuity of care for patients with diabetes represents
good value for money.
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OBJECTIVES: Combination therapy, with either repaglinide or
nateglinide in addition to metformin, is typically initiated in
patients with type 2 diabetes unable to achieve glycemic control
with monotherapy. The efﬁcacy and safety of treatment with
these two therapies in combination with metformin has been
evaluated in a head-to-head clinical trial over 16 weeks in type
2 diabetes patients with an inadequate response to sulphonylurea
or metformin alone. The study demonstrated that after 16 weeks
of therapy, patients treated with Repag+Met had lower HbA1c
levels than those treated with Nateg+Met (-1.28% vs -0.67%).
METHODS: A published and peer-reviewed model for type 2
diabetes was used in the analysis to project the impact of treat-
ment with repaglinide and nateglinide, on long-term outcomes
including life expectancy, quality-adjusted life expectancy and
lifetime costs in the Finnish setting. Annual medication costs in
each treatment arm were calculated using the median end of trial
doses. Direct medical costs of treating diabetes-related compli-
cations used in the analysis were collected from published liter-
ature. Outcomes were discounted at 5% annually, in line with
Finnish recommendations. RESULTS: Repaglinide was projected
to increase life expectancy (0.12 years) and quality-adjusted life
expectancy (0.11 years) compared to nateglinide. Lifetime costs
in patients treated with repaglinide were projected to be €2627
lower than nateglinide. Improvements in long-term outcomes
were attributed to a delayed onset of diabetes-related complica-
tions, particularly those associated with retinopathy and
nephropathy. CONCLUSIONS: In combination with metformin,
repaglinide was projected to be dominant to nateglinide, with
improvements in LE, QALE and costs, in the Finnish setting.
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OBJECTIVE: To present the structure and design of a Markov
model intended to determine the cost-effectiveness of the
FreeStyle Navigator™ continuous glucose monitoring system
(NAV) which provides real-time, glucose level readings while
also measuring and displaying the rate and direction of glucose
level changes. The model compares self-monitoring of blood
glucose (SMBG) to the use of NAV in patients with insulin-
requiring Type 1 diabetes who are either trained or untrained in
proper glycemic management, highlighting the ability of each
monitoring device to predict hypoglycemia and hyperglycemia.
METHODS: The model was constructed using probability and
utility values derived from published clinical literature, and sim-
ulates distributions for each monitoring approach into one of ten
diabetic health states. Treatment costs are based on retail prices
and current Medicare reimbursement rates. Cost and effective-
ness values are accumulated monthly over a 36-month period,
yielding incremental cost-effectiveness ratios (ICER) in dollars
per quality-adjusted life month ($/QALM). RESULTS: Model
analysis demonstrates that the use of NAV by a patient trained
in diabetes management is more cost-effective than SMBG.
Although NAV has a higher overall cost of treatment as com-
pared to SMBG ($12,831 v. $8044), it also has a greater effec-
tiveness (57.8QALM v. 44.3QALM), resulting in an ICER of
$355/QALM ($4,269/QALY) for NAV over SMBG. The glucose
level rate of change and trend information provided by the
FreeStyle Navigator™ has been shown to allow appropriately
trained patients to improve upon decisions regarding self-
treatment to better prevent hypo- and hyperglycemic episodes;
resulting in a lower overall treatment cost and higher overall
effectiveness as compared to the use of NAV by an untrained
patient. CONCLUSION: Based on current performance attrib-
utes, a device such as NAV would be more cost-effective than
traditional glucose monitoring options, meeting the willingness-
to-pay threshold of $50,000/QALY commonly used by payers
for the adoption of new technology.
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OBJECTIVES: Clinical evidence suggests that achieving recom-
mended lipid levels reduces the likelihood of CHD events and
mortality. The beneﬁts of statins on LDL-Cholesterol reduction
have been well established, however, improving other lipid para-
meters can contribute to further CHD risk reduction, as low
HDL-C has been shown to be a strong independent risk factor
for CHD. This cost-effectiveness model was developed to deter-
mine the incremental cost of meeting additional recommended
lipid levels when fenoﬁbrate is added to statin therapy in dia-
betic or metabolic syndrome (MS) patients. METHODS: A sim-
ulation model was designed to predict changes in lipid levels
[HDL-C, LDL-C, triglycerides (TG), total cholesterol (TC)] and
associated drug costs based on Wholesale Acquisition Costs over
the course of 1 year. Lipid targets were based on NCEP-ATP III.
A hypothetical cohort of 1000 was modeled for each disease with
abnormal lipid levels based on NHANES data. Comparators for
diabetic patients were atorvastatin and atorvastatin/fenoﬁbrate
combination. Lipid reductions for diabetic patients were based
on the study by Athyros et al. 2002. Comparators for MS were
simvastatin and simvastatin/fenoﬁbrate combination, and lipid
reductions for MS patients were based on the SAFARI trial.
RESULTS: In a cohort of 1000, adding fenoﬁbrate to atorvas-
tatin resulted in 547 more diabetic patients reaching TG targets
and 483 more reaching HDL-C targets. For MS, adding fenoﬁ-
brate to simvastatin resulted in 549 more patients reaching TG
targets, and 288 more reaching HDL targets. 555 more patients
in the diabetic group achieved at least 3 targets while 525 more
MS patients reached at least 3 targets. The 1 year cost per addi-
tional patient reaching three targets was $1848 for diabetics and
